PureTech Health Plc - ADR
PRTC
Get informed when a big investor buys or sells
+ FollowMarket Cap$41.95M
Close$
$3.59
79.3% downside
Current Fair Value
79.3% downsideOvervalued by 79.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $41.95 Million |
|---|---|
| Enterprise Value | $-61,970,054.00 |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-46 |
| Beta | 0.76 |
| Outstanding Shares | 2,413,547 |
Return
| Return on Equity | 13.50% |
|---|---|
| Return on Assets | 8.18% |
| Return on Invested Capital | -8.54% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | 3.48 |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | 338.81 |
| Enterprise Value to EBIT | -83.09 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
$24.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.77%▲ 1.85% |
|---|---|
| Total Invested | $1.96M▲ 23.75% |
| Investors Holding | 50% |
ESG Score
No data
About PureTech Health Plc
66 employees
CEO: Daphne Zohar PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurologic...